Skip to Main Content

Paper Details

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Clin Cancer Res
41
2020
Author NameAffiliation
Tara L LinUniversity of Kansas
John T SchillerDavid Geffen School of Medicine at university of california los angeles
Prapti PatelUniversity Hospital Bone Marrow Transplant Clinic
  • 1 - 3

Datasets

Release 1.2